BioCanRx
BioCanRx is a Canadian not-for-profit research network founded in 2014 that funds and accelerates the translation of cancer immunotherapy discoveries — including CAR T, oncolytic viruses, mAbs, and RNA vaccines — into clinical trials through competitive grants, GMP biomanufacturing facilities, training programs, and a national network of academic, clinical, and industry partners.
- Company typePrivate
- Founded2014
- HeadquartersOttawa, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BioCanRx does
BioCanRx is a Canadian not-for-profit research network founded in 2014 and hosted by the Ottawa Hospital Research Institute, dedicated to translating cancer immunotherapy discoveries into clinical trials. Its core technical scope spans CAR T-cell therapies (notably the CLIC-1901 CD19-targeting product manufactured domestically via a point-of-care network spanning Vancouver, Victoria, and Ottawa), oncolytic viral immunotherapies (including Maraba virus and Ad-MG1-MAGEA3 platforms), monoclonal antibodies (via the Immunotherapy Monoclonal Antibody Platform, IMAP), RNA-based vaccines, tumor-infiltrating lymphocyte therapy, and radiolabeled antibody therapies. The network operates four core facilities — the GMP-compliant Biotherapeutics Manufacturing Centre (BMC), IMAP at IRCM, the Molecular and Cellular Immunology Core (MCIC) supporting 50–60 projects annually, and IRICoR for commercialization — providing researchers with biomanufacturing, analytics, and drug discovery infrastructure that meets ICH Q10, Health Canada, and FDA standards.
The organization funds translational research through competitive peer-reviewed programs (Catalyst, Enabling, Clinical Trials, and Clinical, Social & Economic Impact studies), with the 2024–2025 cycle alone supporting 20 research projects and four core facilities. BioCanRx's revenue model is dominated by federal government funding — primarily through the Strategic Science Fund (~$38M awarded in May 2024, with a $12.5M tranche in April 2025) — supplemented by partner and industry co-funding from organizations such as the Ontario Institute for Cancer Research, Mitacs, the Terry Fox Research Institute, the Canadian Cancer Society, and the Cancer Research Society. Customer segments are horizontal: academic researchers and clinician-scientists at more than 10 Canadian universities and research hospitals are the primary users of funding and core facilities; cancer patients and advocates engage through the Cancer Stakeholder Alliance and Learning Institute; industry partners (including biotech spinouts such as Turnstone Biologics and Virica Biotech) access manufacturing capacity and technology transfer; and trainees participate via CanPRIME biomanufacturing micro-credentials, the Summer Studentship program, and the HQP Association. The go-to-market motion is community-led, with the annual Summit for Cancer Immunotherapy (Summit4CI, 300+ attendees) serving as the principal convening and knowledge-mobilization channel.
BioCanRx firmographics
Firmographics- Name
- BioCanRx
- Legal name
- BioCanRx
- Website
- https://biocanrx.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioCanRx is a Canadian not-for-profit research network founded in 2014 that funds and accelerates the translation of cancer immunotherapy discoveries — including CAR T, oncolytic viruses, mAbs, and RNA vaccines — into clinical trials through competitive grants, GMP biomanufacturing facilities, training programs, and a national network of academic, clinical, and industry partners.
- Ownership category
- akta.pro rank
BioCanRx industry classification
Industry- Product category
- Cancer Immunotherapy Research Network
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
- akta.pro secondary industries
- Translational Medicine & Biomarkers (HLAIALAF), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where BioCanRx is headquartered
LocationHeadquarters
- HQ city
- Ottawa
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
BioCanRx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Federal Government Research Funding: BioCanRx receives federal funding primarily through the Government of Canada's Strategic Science Fund to support translational cancer immunotherapy research, clinical trials, core facilities, and training programs. This is the dominant revenue stream enabling network operations.
- Partner and Industry Contributions: Co-funding and in-kind contributions from industry partners, provincial governments, and charitable organizations supplement federal funding to support specific projects, core facilities, and training initiatives.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
BioCanRx product offering
Product offeringCore offering
BioCanRx is Canada's Immunotherapy Network — a not-for-profit research network that funds and actively supports the translation, manufacture, and adoption of cancer immunotherapies. The organization operates as a network-based platform providing competitive research funding, access to GMP biomanufacturing core facilities, training programs, and the CLIC Network for made-in-Canada CAR T-cell therapies, with the goal of moving promising discoveries from the lab into clinical trials.
Product overview
BioCanRx is Canada’s Immunotherapy Network — a research funding and support organization that operates as a platform of interconnected programs to accelerate cancer immunotherapy from discovery to clinical trials. The organization provides competitive translational research funding (Catalyst, Enabling, Clinical Trial, and CSEI programs), supports access to four core biomanufacturing and immunology facilities (IMAP, BMC, MCIC, IRICoR), operates the CanPRIME biomanufacturing training program, manages the annual Summit4CI conference and Learning Institute, and funds the made-in-Canada CLIC-1901 CAR T cell therapy. BioCanRx Summer Studentships engage undergraduate researchers, while patient resources provide immunotherapy education. The network connects academic researchers with manufacturing facilities, clinical trial infrastructure, and commercialization expertise to translate discoveries into treatments.
Differentiator
Problem solved
Functional benefit
Brands
- Summit4CI: Annual Summit for Cancer Immunotherapy bringing together scientists, clinicians, students, industry, patient groups, and government representatives.
- CLIC Network
- CanPRIME
- Learning Institute
- Summer Studentship Program
Products and services
- BioCanRx Research Funding Programs
- CLIC-1901 CAR T Cell Therapy
- Core Facility Access
- CanPRIME Biomanufacturing Training Program
- Summit4CI (Summit for Cancer Immunotherapy)
- Learning Institute
- BioCanRx Summer Studentships
- CLIC Network
Quantifiable outcome
- Over 40 made-in-Canada clinical trials supported through the network
- +4 more outcomes
Companies that use BioCanRx
Customer profileNamed customers11 records
Segments4 records
Ideal customer profiles4 records
BioCanRx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
BioCanRx partnerships and signals
Strategic signalPartnerships
28 partnerships are on record, tiered core and minor.
- Cancer Research SocietycoreLead partner in a $25-million multi-partner national clinical cancer research program. BioCanRx is one of several cancer research funders collaborating to support investigator-initiated clinical trials for rare, underserved, and low-survival cancers across Canada. The program provides grants of up to $2 million over five years.
- Canadian Cancer SocietycoreCo-funder of the $25-million national clinical cancer research program supporting investigator-initiated clinical trials for rare and underserved cancers.
- Terry Fox Research InstitutecoreCo-funder of the $25-million national clinical cancer research program. BioCanRx and TFRI have a history of co-funding translational cancer research initiatives.
- Lotte & John Hecht Memorial FoundationminorFunder of the $25-million multi-partner clinical cancer research program.
- Génome QuébecminorFunder of the $25-million multi-partner clinical cancer research program.
- SickKids Garron Family Cancer CentreminorPartner funder of the $25-million multi-partner clinical cancer research program.
- Kindred FoundationminorPartner funder of the $25-million multi-partner clinical cancer research program.
- Childhood Cancer CanadaminorPartner funder of the $25-million multi-partner clinical cancer research program.
- Institut du cancer de MontréalminorPartner funder of the $25-million multi-partner clinical cancer research program.
- Ottawa Hospital Research Institute (OHRI)coreBioCanRx is hosted by the Ottawa Hospital Research Institute. OHRI provides institutional infrastructure including the Biotherapeutics Manufacturing Centre, a world-class GMP facility with over 17 years of experience supporting BioCanRx projects.
- BC CancercoreNetwork partner providing the Conconi Family Immunotherapy Lab for CAR T cell manufacturing and the Genome Sciences Centre for plasmid manufacturing. Also hosts the Molecular and Cellular Immunology Core (MCIC).
- McMaster UniversitycoreNetwork partner providing research facilities including the McMaster Immunology Research Centre for recombinant virus production. Home to key BioCanRx investigators such as Dr. Brian Lichty.
- Dalhousie UniversitycoreNetwork partner institution with researchers engaged in BioCanRx-funded projects in cancer immunotherapy.
- University of OttawacoreNetwork partner and host university for BioCanRx-hosted OHRI. Key research collaborator in CAR T and viral immunotherapy programs.
- University of British ColumbiacoreNetwork partner institution with researchers at UBC and affiliated institutions contributing to BioCanRx-funded research.
- The Hospital for Sick Children (SickKids)coreNetwork partner providing pediatric clinical trial sites for CAR T therapy. Partner in the $25-million multi-partner clinical research program.
- Queen's UniversitycoreNetwork partner institution with researchers engaged in BioCanRx-funded cancer immunotherapy projects.
- McGill University / Centre Hospitalier de l'Université de Montréal (CHUM)coreNetwork partner institution contributing researchers and clinical expertise to BioCanRx-funded projects.
- Carleton UniversitycoreNetwork partner institution collaborating on BioCanRx-funded cancer immunotherapy research.
- University Health Network (UHN)coreNetwork partner hosting Princess Margaret Cancer Centre, a major adult clinical trial site for BioCanRx-funded CAR T trials. Dr. Marcus Butler leads Canadian-developed CAR T-cell therapy trials.
- IRCM (Institut de recherches cliniques de Montréal)coreHosts the Immunotherapy Monoclonal Antibody Platform (IMAP), a first-of-its-kind academic mAb facility in Canada established in 2020. Led by Dr. André Veillette, IMAP provides access to cutting-edge platforms for accelerating monoclonal antibody development for cancer treatment.
- IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research)coreNational leader in drug discovery and commercialization at Université de Montréal. Through a BioCanRx agreement, projects access IRICoR's scientific operations, IP strategies, business development, and industry collaboration support to move assets toward commercialization.
- Turnstone Biologics Inc.coreOttawa-based biotech spinout from BioCanRx network research (Bell, Lichty, Stojdl). BioCanRx supported early development of Turnstone's oncolytic viral immunotherapy platform, including the Ad-MG1-MAGEA3 product. Turnstone subsequently partnered with AbbVie in a major global collaboration. Recognized as one of the top 15 biotech start-ups in the world (FierceBiotech's 2017 Fierce 15).
- Virica BiotechminorOttawa-based biotech company that received timely BioCanRx investment to develop biomanufacturing tools that decrease the cost of manufacturing vaccines and biotherapeutics. CEO Dr. Jean-Simon Diallo is a network investigator at OHRI. Virica's innovations have enhanced biomanufacturing efficiency for network partners and have global commercialization potential.
- IndspireminorIndigenous-led charity providing mentorship for Indigenous students who receive BioCanRx Summer Studentships through the Rivers to Success program, offering one-on-one and group guidance from Indigenous peers and role models.
- Algonquin CollegecorePartner with BioCanRx and the University of Ottawa in developing a micro-credential in good manufacturing practices (GMP) for biomanufacturing. Algonquin's college-level training complements university-level offerings in the CanPRIME program.
- Let's Talk ScienceminorNational organization providing hands-on science outreach. BioCanRx partners with Let's Talk Science to deliver cancer immunotherapy lessons, lab tours, and workshops in Canadian high schools, engaging over 10,000 students to date.
- Alberta Cell Therapy Manufacturing Facility (ACTM)minorGMP cell manufacturing facility in Edmonton that received technology transfer from BioCanRx network researchers (Levings Lab) for thymic Treg manufacturing through the Lab Exchange program.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
BioCanRx competitors and assessment
Company assessmentDirect peers
- Parker Institute for Cancer Immunotherapy (PICI): PICI is a US-based non-profit that funds and coordinates cancer immunotherapy research across leading academic centers, with a strong focus on translational science and clinical trials. PICI is BioCanRx's closest functional analog as a multi-institutional cancer immunotherapy research network.
- Cancer Research Institute (CRI): CRI is a US non-profit that has funded immunology and cancer immunotherapy research for decades, supporting investigator-initiated translational grants and clinical trials. Like BioCanRx, CRI bridges academic discovery and clinical application in immuno-oncology.
- Stand Up To Cancer (SU2C): SU2C is a major US charitable funder of translational cancer research, including multi-institutional "Dream Teams" focused on specific cancer types and modalities. Its model of funding collaborative translational teams closely parallels BioCanRx's network approach.
- Ludwig Institute for Cancer Research: Ludwig is an international non-profit cancer research organization that operates across multiple centers, with significant translational and immunotherapy programs. It is comparable as a globally distributed, academically anchored cancer research network.
- Terry Fox Research Institute: TFRI is a Canadian non-profit that funds pan-Canadian translational cancer research, including the recently co-funded $25M multi-partner clinical research program with BioCanRx. TFRI is both a peer and an active partner.
- Cancer Research Society: CRS is a Canadian non-profit cancer research funder, lead partner in the $25M multi-partner clinical research program with BioCanRx. It is comparable as a Canadian cancer research funding organization, though with a broader scope beyond immunotherapy.
Others
- Society for Immunotherapy of Cancer (SITC): SITC is a professional society that advances cancer immunotherapy through education, conferences, and scientific exchange. While not a funder like BioCanRx, SITC operates similar community/convening functions in immuno-oncology (e.g., annual meetings akin to Summit4CI).
- Ottawa Hospital Research Institute: OHRI is the host institution for BioCanRx and provides core infrastructure including the Biotherapeutics Manufacturing Centre. As BioCanRx's institutional home and primary research partner, OHRI is functionally co-located rather than a competing entity.
Emerging players
- Cellares: Cellares is an emerging cell therapy manufacturing automation company whose Cell Shuttle platform competes with the closed/automated point-of-care manufacturing concept that BioCanRx's CLIC network has built around. Both target decentralized, scalable CAR T production.
Broad incumbents
- Lonza Cell & Gene Technologies: Lonza is a major global CDMO with extensive cell and gene therapy manufacturing capacity, including GMP viral vector and cell therapy production. As BioCanRx scales its BMC and CLIC manufacturing, Lonza is a global incumbent competitor for outsourced GMP services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioCanRx social profiles
Digital presenceBioCanRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioCanRx leadership team
Management profileNumber of profiles
Profiles5 records
BioCanRx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioCanRx M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioCanRx
What does BioCanRx do?
BioCanRx is Canada's Immunotherapy Network — a not-for-profit research network that funds and actively supports the translation, manufacture, and adoption of cancer immunotherapies. The organization operates as a network-based platform providing competitive research funding, access to GMP biomanufacturing core facilities, training programs, and the CLIC Network for made-in-Canada CAR T-cell therapies, with the goal of moving promising discoveries from the lab into clinical trials.
Is BioCanRx a public or private company?
BioCanRx is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was BioCanRx founded?
BioCanRx was founded in 2014. It employs 11 to 50 people.
Where is BioCanRx based?
BioCanRx is headquartered in Ottawa, Canada, in the North America region.
How does BioCanRx make money?
Two revenue lines are on record. Federal Government Research Funding is the primary driver. The others are partner and Industry Contributions.
Who are BioCanRx's main competitors?
Direct peers on record are Parker Institute for Cancer Immunotherapy (PICI), Cancer Research Institute (CRI), Stand Up To Cancer (SU2C), Ludwig Institute for Cancer Research, Terry Fox Research Institute and Cancer Research Society. Others are Society for Immunotherapy of Cancer (SITC) and Ottawa Hospital Research Institute. Cellares is listed as an emerging player. Lonza Cell & Gene Technologies is listed as a broad incumbent.
Does BioCanRx have an API?
No public API is recorded for BioCanRx.
What industry is BioCanRx in?
BioCanRx's product category is Cancer Immunotherapy Research Network. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 8731.